ELIXIR MD Secures Groundbreaking FDA Clearance for Soft Tissue Coagulation in Plastic Surgery

ELIXIR MD, a global leader in photobiomodulation technology, has achieved a significant milestone by becoming the first and only LED light therapy device to secure FDA clearance for soft tissue coagulation in plastic surgery. This approval marks a pivotal moment in the field, allowing plastic surgeons to utilise ELIXIR MD’s cutting-edge technology in a variety of procedures to improve post-surgical outcomes.

The device employs ELIXIR MD’s proprietary EPBM (Enhanced Photobiomodulation) technology, which uses specific wavelengths of light to promote cellular activity, thereby accelerating healing, reducing inflammation, and minimising scarring. This new clearance expands the product’s scope, allowing it to provide faster, more efficient recovery in plastic surgery patients.

Ewan Yassen, CEO of ELIXIR MD, highlighted the importance of this advancement, stating, “The new indication enhances the product’s use, helping practitioners expand their patient base and improve post-operative recovery.” Currently, more than 70 plastic surgeons globally are already utilising ELIXIR MD, setting a new standard for LED light therapy in the industry.